APD was upgraded from Hold to Buy, Argus Research said. $94 price target. Company should benefit from stronger global economic activity.
CELG upgraded to Buy from Neutral. Valuation call, Bank of America/Merrill Lynch said. Price target increased to $70 from $64.
CF was upgraded from Sell to Neutral, UBS said. Valuation call, based on a $84 price target. Estimates also boosted, because of a better natural gas outlook.
DG was downgraded from Buy to Neutral, MKM Partners said. Valuation call, as the stock is up 32% year-to-date. $29 price target.
DV downgraded to Neutral from Outperform. Higher than expected regulatory, counter cyclicality and execution risk, Credit Suisse said. Price target lowered to $65 from $75.
EFX coverage initiated at Bank of America/Merrill Lynch with a Neutral rating and $38 price target. Cyclical tailwinds factored in, analysts said.
ESI downgraded to Neutral from Outperform. Weak guidance and lower-than-expected earnings, Credit Suisse said. Price target sunk to $110 from $135.
FITB was downgraded from Buy to Hold, Collins Stewart said. Valuation call.
FMBI was downgraded from Outperform to Perform, Oppenheimer said. Valuation call, even though the company delivered strong first quarter results.
HEW was upgraded from Sell to Neutral, Goldman Sachs said. $41 price target. Estimates also boosted, given higher BPO margins and improving consulting demand.
HOT was upgraded from Hold to Buy, Stifel Nicolaus said. Lodging recovery is underway and the company can leverage its real estate platform. $70 price target.
JCI price target lifted by a dollar to $36 after 2Q10 beat, Barclays said. 2010 and 2011 EPS estimates raised to $2 and $2.60, respectively. Equal Weight rating.
JCI was upgraded from Neutral to Outperform, Robert Baird said. $42 price target. Company has strong growth potential in China and should see a rapid recovery in margins.
MDAS upgraded to Overweight from Equal Weight on improving trends in the company's customer base, Barclays said. Price target raised by a dollar to $27. 2010 and 2011 EPS estimates held at $0.77 and $0.95, respectively.
NWL was downgraded from Outperform to Market Perform, BMO Capital Markets said. Valuation call, based on a $17 price target.
PRSP was downgraded from Outperform to Market Perform, Suntrust, Robinson Humphrey said. Valuation call, even though the company had a solid first quarter.
SPW upgraded to Buy from Neutral as the industrial economy has entered an expansion phase that can be sustained, Bank of America/Merrill Lynch said. Price target surged to $87 from $58.
SYY was upgraded from Neutral to Buy, UBS said. $37 price target. Estimates also raised, because of improving restaurant trends.
TMO was upgraded from Hold to Buy, Jefferies said. $62 price target. Company should benefit from industrial recovery.
TRMK was downgraded from Outperform to Market Perform, Keefe, Bruyette & Woods said. Valuation call, based on a $28 price target.
TSS coverage initiated with an Underperform rating and $16 price target. Persistent headwinds, Bank of America/Merrill Lynch said. EPS growth could resume in 2011.
VMW was initiated with a Buy rating, MKM Partners said. $80 price target. Company should deliver significant free cash flow growth over the next two years.
ZMH upgraded at JP Morgan. Rating raised to Overweight from Neutral. Price target raised to $70 from $68. Maintains 2010 EPS estimates of $4.27.
AONE price target lowered to $17 from $18 on concerns over Chrysler relationship, Barclays said. AONE could likely receive DOE funding soon. Equal Weight rating.
American Express numbers boosted at Goldman
Shares of AXP now seen reaching $50, according to Goldman Sachs. Estimates also upped, because of improving credit and cost trends. Neutral rating.
Shares of AXP now seen reaching $50, according to Goldman Sachs. Estimates also upped, because of improving credit and cost trends. Neutral rating.
BEC estimates were reduced through 2012, Morgan Stanley said. Troponin should weigh on earnings and the company is spending more on quality control. Equal-weight rating.
BSX estimates were upped through 2011, UBS said. Company should see sales recover, with the sales halt removed. Buy rating and $8 price target.
BUCY etimates were upped through 2011, Morgan Stanley said. Channel checks suggest better mining results. Overweight rating and new $80 price target.
CAH estimates were boosted through 2011, UBS said. Company should benefit from a strong generic drug pipeline. Buy rating and new $43 price target.
Shares of CSCO now seen reaching $32, according to Oppenheimer. Estimates also increased, following positive channel checks. Outperform rating.
DG price target raised to $36 from $30 on consistent execution and growth prospects, Bank of America/Merrill Lynch said. Reiterate Buy rating.
Shares of DOV now seen reaching $63, according to Morgan Stanley. Company is seeing higher order trends and deserves a higher multiple. Overweight rating.
GLW estimates were increased through 2012, Goldman Sachs said. Inventory remains tight in the LCD supply chain. Buy rating.
HCBK estimates were cut through 2011, FBR Capital Markets said. Company is seeing slower balance sheet growth. Outperform rating and new $15 price target.
Shares of HON now seen reaching $47, according to UBS. Estimates also increased, given better end-market demand and M&A opportunities. Neutral rating.
Shares of IR now seen reaching $38, according to Morgan Stanley. Estimates also increased, given stronger orders. Equal-weight rating.
MEE estimates were cut through 2012, Goldman Sachs said. Company will likely faces rising costs. Neutral rating and new $50 price target.
NKE estimates were raised through 2012, Goldman Sachs said. Company likely to talk up accelerating growth trends at its upcoming investor meeting. Buy rating and new $85 price target.
ORLY price target lifted to $52 from $46 as 1Q10 is expected to benefit from early spring and DC progress, Bank of America/Merrill Lynch said. Maintain Buy rating.
Shares of PCX now seen reaching $25, according to Goldman Sachs. Estimates also upped, given the company's new production guidance and lower expected costs. Sell rating.
RTN estimates were boosted through 2012, Goldman Sachs said. Company will likely repurchase more shares. Neutral rating and new $52 price target.
SLB price target jumped to $92 from $84 as the international recovery is ahead of expectations, Citigroup said. 2010 and 2011 EPS estimates lifted to $2.95 and $3.65, respectively. Maintain Buy rating.
VZ price target lowered a dollar to $32 on expected lower wireline margins, Barclays said. 2010 and 2011 EPS estimates sunk to $2.14 and $2.31, respectively. Maintain Equal Weight rating.
Shares of WBS now seen reaching $18, according to FBR Capital Markets. Estimates also raised, given lower credit costs. Market Perform rating.
Shares of WCC now seen reaching $47, according to UBS. Estimates also raised, as the company is seeing higher industrial sales and is paying down debt. Buy rating.
S&P 500 now seen reaching 1,350 by year-end, UBS said. Earnings estimates also increased through 2011, given potential margin expansion.